MedPath

Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Phase 3
Completed
Conditions
Benign Prostatic Hypertrophy
Interventions
Registration Number
NCT00663858
Lead Sponsor
AEterna Zentaris
Brief Summary

Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and among those aged 50 to 80, about 40% report moderate or severe urinary symptoms of prostatism. The aim of treatment is to improve patients' quality of life which primarily depends on the severity of the symptoms of BPH. Current treatments of BPH have a benefit / risk ratio which leaves room for improvement.

For this study, study medication (Cetrorelix pamoate or placebo) is administered by injection in the buttocks (Intramuscular). All patients completing the double-blind portion (Week 0 to 52) are eligible to receive the active drug during the open-label part of the study (Week 52 to 90).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
420
Inclusion Criteria
  • Benign Prostatic Hyperplasia, based on medical history
  • Voiding symptoms
Exclusion Criteria
  • Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder
  • Major organ dysfunction
  • Eczema (atopic dermatitis) treated during the last 6 months
  • Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with α blockers or saw palmetto within the last 6 weeks prior to randomization
  • Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy
  • History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cetrorelix 78+78Cetrorelix 78+78-
Cetrorelix 78 + PlaceboCetrorelix 78 + Placebo-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
International Prostate Symptom Score (IPSS)Baseline and 52 weeks

IPSS score of BPH symptoms based on a patient questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total overall score range: 0 points (best) to 35 points (worst)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (49)

4th City Hospital

🇧🇾

Minsk, Belarus

Privat urological ambulance

🇨🇿

Plzen, Czech Republic

1st Medical Faculty of Charles University, Deputy Department and Clinic of Urology

🇨🇿

Praha, Czech Republic

Minsk Regional Clinical Hospital, Clinic of Urology

🇧🇾

Minsk, Belarus

Urocentrum Prague, Out-Patient Clinic of Urology

🇨🇿

Prague, Czech Republic

Policlinic Pod Marjánkou 12, Urological Department

🇨🇿

Prague, Czech Republic

Faculty hospital Na Bulovce

🇨🇿

Praha, Czech Republic

University of Bari, Department of Urology

🇮🇹

Bari, Italy

Hopital Edouard Heriot Service Urologie

🇫🇷

Lyon, France

National Central Hospital for Active Treatment of Oncology JSC

🇧🇬

Sofia, Bulgaria

Aleksandrovska Hospital, Kidney Transplantation Department

🇧🇬

Sofia, Bulgaria

Urologische Praxisgemeinschaft Frankfurt Höchst

🇩🇪

Frankfurt, Germany

Multiprofil Hospital "Sveta Anna", Urology Department

🇧🇬

Varna, Bulgaria

Klinikum Offenbach GmbH, Klinik für Urologie

🇩🇪

Offenbach, Germany

Hopital René Dubos Service Urologie 6

🇫🇷

Pontoise, France

Università Federico II Napoli

🇮🇹

Napoli, Italy

Urologische Gemeinschaftspraxis Rulf/Langhorst

🇩🇪

Erkrath, Germany

Androgeos Clinic

🇨🇿

Prague, Czech Republic

19th Central Regional Policlinic, Urology department

🇧🇾

Minsk, Belarus

Urological center Uro-Santé Brumlovka

🇨🇿

Praha, Czech Republic

Irccs Ospedale San Raffaele Milano, Università Vita Salute-San Raffaele

🇮🇹

Milano, Italy

University multiprofil Hospital of Active Treatment "Sveti Georgi", Urology Department

🇧🇬

Plovdiv, Bulgaria

CHU Hôpital Claude Huriez

🇫🇷

Lille, France

Urologische Praxis

🇩🇪

Münster, Germany

Health Center SANUS

🇨🇿

Hradec Králové, Czech Republic

Atrium Medisch Centrum

🇳🇱

Heerlen, Netherlands

Hopital Henri Mondor Service Urologie

🇫🇷

Creteil, France

Pan-Klinik Urologie

🇩🇪

Köln, Germany

Asklepios Klinik Seligenstadt

🇩🇪

Seligenstadt, Germany

Urology Clinic Skopje

🇲🇰

Skopje, Macedonia, The Former Yugoslav Republic of

Streekziekenhuis Koningin Beatrix

🇳🇱

Winterswijk, Netherlands

Leicester General Hospital, Urology Section

🇬🇧

Leicester, United Kingdom

Aleksandrovska Hospital, Oncourology Department

🇧🇬

Sofia, Bulgaria

Praxis Filipas

🇩🇪

Wiesbaden, Germany

C.H.U Rangueil, Service d'Urologie

🇫🇷

Toulouse, France

University of Padova, Department of Urology

🇮🇹

Padova, Italy

Canisius-Wilhelmina Ziekenhuis

🇳🇱

Nijmegen, Netherlands

Andros Mannenkliniek

🇳🇱

Maastricht, Netherlands

Gelre Ziekenhuizen

🇳🇱

Amsterdam, Netherlands

Onze Lieve Vrouwe Gasthuis

🇳🇱

Amsterdam, Netherlands

S.C. Uro Andro Med Srl

🇷🇴

Bucharest, Romania

Spitalul Clinic de Urologie "Prof. Dr. Th. Burghele"

🇷🇴

Bucharest, Romania

Centrul Medical "Sf. Pantelimon"

🇷🇴

Pantelimon, Romania

Spitalul Clinic de Urgenta "Sf. Ioan", Clinica Urologie

🇷🇴

Bucharest, Romania

Clinica Chirurgie Urologica si Transplant Renal

🇷🇴

Bucharest, Romania

Leighton Hospital, Clinical Trials Dept., Michael Heal Unit

🇬🇧

Crewe, Cheshire, United Kingdom

Bristol Royal Infirmary, Urology Research Unit

🇬🇧

Bristol, United Kingdom

Urologische Klinik, Ev. Krankenhaus Oberhausen

🇩🇪

Oberhausen, Germany

Freeman Hospital, Urology Clinic

🇬🇧

Newcastle upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath